Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Arch Biopartners - My Due Diligence

<< Previous

Bullboard Posts

Next >>

Comment by C10H12N2on Jun 08, 2022 12:43am

248 Views

Post# 34739127

RE:Arch Biopartners - My Due Diligence

Yawn. It's all about the data dude. No statistical significance and the stock plummets to less than $1. It's still a COVID-19 play and 99.99% of them around the world have failed. Put that in your due diligence cut and paste next time.

<< Previous

Bullboard Posts

Next >>

Gold vs. bitcoin, where should you invest?